Is p16 immunoreactivity an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma?
According to our data, there is a significant correlation between loss of p16 expression and tumor progression in patients with minimally-invasive bladder cancer. Immunohistochemical p16 staining may therefore represent a useful tool of providing additional information on the clinical outcome of these patients.
Per2 modulates EPC mobilization and function after MI, which is important to recovery after MI in mice.